Related references
Note: Only part of the references are listed.Minimal modification in the factor VIII B-domain sequence ameliorates the murine hemophilia A phenotype
Joshua I. Siner et al.
BLOOD (2013)
Therapeutic levels of FVIII following a single peripheral vein administration of rAAV vector encoding a novel human factor VIII variant
Jenny McIntosh et al.
BLOOD (2013)
Generation of an optimized lentiviral vector encoding a high-expression factor VIII transgene for gene therapy of hemophilia A
J. M. Johnston et al.
GENE THERAPY (2013)
Recent Progress in Gene Therapy for Hemophilia
Marinee K. Chuah et al.
HUMAN GENE THERAPY (2012)
A bispecific antibody to factors IXa and X restores factor VIII hemostatic activity in a hemophilia A model
Takehisa Kitazawa et al.
NATURE MEDICINE (2012)
Lentiviral vector common integration sites in preclinical models and a clinical trial reflect a benign integration bias and not oncogenic selection
Alessandra Biffi et al.
BLOOD (2011)
Incidence of factor VIII inhibitors throughout life in severe hemophilia A in the United Kingdom
Charles R. M. Hay et al.
BLOOD (2011)
Hepatocyte-Targeted Expression by Integrase-Defective Lentiviral Vectors Induces Antigen-Specific Tolerance in Mice with Low Genotoxic Risk
Janka Matrai et al.
HEPATOLOGY (2011)
Successful Pregnancy After Busulfan/Cytoxan Conditioning Regimen for AML
Ami J. Shah
JOURNAL OF PEDIATRIC HEMATOLOGY ONCOLOGY (2011)
Sensitivity of whole blood clotting time and activated partial thromboplastin time for factor IX: relevance to gene therapy and determination of post-transfusion elimination time of canine factor IX in hemophilia B dogs
T. C. NICHOLS et al.
JOURNAL OF THROMBOSIS AND HAEMOSTASIS (2011)
Efficacy and Safety of Long-term Prophylaxis in Severe Hemophilia A Dogs Following Liver Gene Therapy Using AAV Vectors
Denise E. Sabatino et al.
MOLECULAR THERAPY (2011)
Adenovirus-Associated Virus Vector-Mediated Gene Transfer in Hemophilia B
Amit C. Nathwani et al.
NEW ENGLAND JOURNAL OF MEDICINE (2011)
Platelet gene therapy improves hemostatic function for integrin αIIbβ3-deficient dogs
Juan Fang et al.
PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA (2011)
A study of variations in the reported haemophilia A prevalence around the world
J. S. Stonebraker et al.
HAEMOPHILIA (2010)
Stable Marking and Transgene Expression Without Progression to Monoclonality in Canine Long-Term Hematopoietic Repopulating Cells Transduced with Lentiviral Vectors
Joerg Enssle et al.
HUMAN GENE THERAPY (2010)
Beyond Clotting: The Powers of Platelets
Mitch Leslie
SCIENCE (2010)
Recombinant canine B-domain-deleted FVIII exhibits high specific activity and is safe in the canine hemophilia A model
Denise E. Sabatino et al.
BLOOD (2009)
Directed Engineering of a High-expression Chimeric Transgene as a Strategy for Gene Therapy of Hemophilia A
Christopher B. Doering et al.
MOLECULAR THERAPY (2009)
Inhibitors of Factor VIII in Black Patients with Hemophilia
Kevin R. Viel et al.
NEW ENGLAND JOURNAL OF MEDICINE (2009)
Identification and characterization of nonapeptide targeting a human B cell lymphoma, Raji
Jin Huk Choi et al.
INTERNATIONAL IMMUNOPHARMACOLOGY (2008)
Successful treatment of canine leukocyte adhesion deficiency by foamy virus vectors
Thomas R. Bauer et al.
NATURE MEDICINE (2008)
Lentivirus-mediated platelet-derived factor VIII gene therapy in murine haemophilia A
Q. Shi et al.
JOURNAL OF THROMBOSIS AND HAEMOSTASIS (2007)
Factor VIII ectopically targeted to platelets is therapeutic in hemophilia A with high-titer inhibitory antibodies
Qizhen Shi et al.
JOURNAL OF CLINICAL INVESTIGATION (2006)
Therapeutic expression of the platelet-specific integrin, αIIbβ3, in a murine model for Glanzmann thrombasthenia
J Fang et al.
BLOOD (2005)
Intracellular interaction of von Willebrand factor and factor VIII depends on cellular context: lessons from platelet-expressed factor VIII
H Yarovoi et al.
BLOOD (2005)
Dog star rising: The canine genetic system
NB Sutter et al.
NATURE REVIEWS GENETICS (2004)
Conditional suppression of cellular genes: Lentivirus vector-mediated drug-inducible RNA interference
M Wiznerowicz et al.
JOURNAL OF VIROLOGY (2003)
Expression of human factor VIII under control of the platelet-specific αIIb promoter in megakaryocytic cell line as well as storage together with VWF
Q Shi et al.
MOLECULAR GENETICS AND METABOLISM (2003)
Real-time quantitative reverse transcriptase-polymerase chain reaction as a method for determining lentiviral vector titers and measuring transgene expression
G Lizée et al.
HUMAN GENE THERAPY (2003)
Critical independent regions in the VWF propeptide and mature VWF that enable normal VWF storage
SL Haberichter et al.
BLOOD (2003)
Induction of megakaryocytes to synthesize and store a releasable pool of human factor VIII
DA Wilcox et al.
JOURNAL OF THROMBOSIS AND HAEMOSTASIS (2003)
Correction of a large animal model of type I Glanzmann's thrombasthenia by nonmyeloablative bone marrow transplantation
GP Niemeyer et al.
EXPERIMENTAL HEMATOLOGY (2003)
Gene therapy for platelet disorders: studies with Glanzmann's thrombasthenia
DA Wilcox et al.
JOURNAL OF THROMBOSIS AND HAEMOSTASIS (2003)
The Chapel Hill hemophilia A dog colony exhibits a factor VIII gene inversion
JN Lozier et al.
PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA (2002)
The von Willebrand factor propeptide (VWFpp) traffics an unrelated protein to storage
SL Haberichter et al.
ARTERIOSCLEROSIS THROMBOSIS AND VASCULAR BIOLOGY (2002)
Laboratory diagnosis of inhibitors
MA Sahud
SEMINARS IN THROMBOSIS AND HEMOSTASIS (2000)